Kymera Therapeutics
CAMBRIDGE · Biopharma, Biotechnology, Pharmaceutical · 135 employees
Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrad
Funding history
- Funding Round — $602.0M — Dec 2025
- Series series c — $102.0M — Mar 2020
Recent signals
- Dec 10, 2025: Raised $602.0M
- Jun 25, 2025: Kymera Therapeutics partners with Gilead Sciences to develop molecular glue degraders for cancer treatment.
- Apr 09, 2025: Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
- Oct 24, 2024: Launched Kymera Therapeutics Launches Phase 1 Clinical Trial for KT-621, a Novel Oral STAT6 Degrader for Immuno-Inflammatory Diseases.
- Aug 19, 2024: Kymera Therapeutics Announces Proposed Public Offering
- Mar 12, 2020: Raised $102.0M in Series series c
See plans & pricing → Track Kymera Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.